Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial

Creative Commons License

Giugliano R. P., Keech A., Murphy S. A., Huber K., TOKGÖZOĞLU S. L., Lewis B. S., ...Daha Fazla

JAMA CARDIOLOGY, cilt.2, sa.12, ss.1385-1391, 2017 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 2 Sayı: 12
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1001/jamacardio.2017.3944
  • Dergi Adı: JAMA CARDIOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1385-1391
  • Hacettepe Üniversitesi Adresli: Evet

Özet

IMPORTANCE Current guidelines for atherosclerotic cardiovascular disease focus on high-intensity statins and targeting or using a threshold low-density lipoprotein cholesterol (LDL-C) level of less than 70 mg/dL for the highest-risk patients. Whether further reduction of LDL-C beyond these boundaries would be beneficial is unknown.